Population Pharmacokinetics and Exposure‐Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus Erythematosus

医学 药代动力学 非金属 人口 协变量 妥珠单抗 药理学 内科学 疾病 统计 数学 环境卫生 英夫利昔单抗
作者
Chayan Acharya,Martin H. Magnusson,Pavan Vajjah,Ruth Oliver,Miren Zamacona
出处
期刊:The Journal of Clinical Pharmacology [Wiley]
标识
DOI:10.1002/jcph.2188
摘要

Systemic lupus erythematosus (SLE) is a systemic, autoimmune disease characterized by chronic inflammation and organ damage. Dapirolizumab pegol inhibits CD40 ligand (CD40L) and is currently undergoing phase 3 trials for the treatment of SLE. To describe the pharmacokinetic characteristics of dapirolizumab pegol and the relationship between exposure and probability of achieving a British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response, a population pharmacokinetic (popPK) model and an exposure-response model were developed, based on results of the phase 2b trial (RISE; NCT02804763) of dapirolizumab pegol in SLE. Dapirolizumab pegol pharmacokinetics were found to be dose proportional and well described by a 2-compartment model with first-order elimination from the central compartment. In the popPK model, body weight was the only significant covariate. The average concentration of dapirolizumab pegol, derived from the popPK model, was incorporated into the exposure-response model. Overall, the exposure-response model showed that treatment with dapirolizumab pegol increased the probability of transitioning from BICLA "Nonresponder" to "Responder." No significant covariates on BICLA responder status were identified. Notably, the half maximal effective concentration was greater for the transition from "Responder" to "Nonresponder" (150 µg/mL) than the transition from "Nonresponder" to "Responder" (12 µg/mL), indicating that sustained dapirolizumab pegol concentrations may be required to maintain BICLA response. In conclusion, dapirolizumab pegol pharmacokinetics were as expected for a PEGylated molecule and results from the exposure-response model indicate that a favorable dapirolizumab pegol effect was identified for both BICLA "Nonresponder" to "Responder" and "Responder" to "Nonresponder" transition probabilities.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
早一点完成签到 ,获得积分10
1秒前
魁梧的傲安完成签到,获得积分10
1秒前
TGU的小马同学完成签到 ,获得积分10
2秒前
kyousan完成签到,获得积分10
4秒前
Hi完成签到,获得积分10
4秒前
小四完成签到,获得积分10
4秒前
诚心巧曼完成签到 ,获得积分10
5秒前
hadfunsix完成签到 ,获得积分10
7秒前
影像大侠完成签到,获得积分10
8秒前
贾贡献的应助被科研通管家采纳,获得20
8秒前
完美世界的应助被科研通管家采纳,获得10
9秒前
yqt完成签到,获得积分10
9秒前
sialiangwei完成签到,获得积分10
10秒前
新德里梅塔洛1号完成签到,获得积分10
11秒前
水water完成签到 ,获得积分10
11秒前
12秒前
优美的冰巧完成签到 ,获得积分10
13秒前
cmaz完成签到 ,获得积分10
15秒前
qiqi完成签到,获得积分10
15秒前
爱学数学的数学小白完成签到,获得积分10
16秒前
wen完成签到 ,获得积分10
16秒前
慢慢完成签到 ,获得积分10
17秒前
firewei完成签到,获得积分10
18秒前
陈琛琛完成签到,获得积分10
19秒前
rice0601完成签到,获得积分10
20秒前
牛魔王完成签到,获得积分10
20秒前
Xu发布了新的文献求助10
21秒前
22秒前
专注笑珊完成签到,获得积分10
22秒前
夕阴完成签到 ,获得积分10
22秒前
zz完成签到,获得积分20
24秒前
butter发布了新的文献求助30
24秒前
researchkslw完成签到,获得积分10
25秒前
夏侯远望完成签到,获得积分10
25秒前
汪汪完成签到 ,获得积分10
25秒前
林美芳完成签到 ,获得积分10
25秒前
shmilycaleb完成签到,获得积分10
26秒前
趁热拿铁完成签到 ,获得积分10
26秒前
渡春屿完成签到 ,获得积分10
26秒前
忧郁小松鼠完成签到,获得积分10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166556
求助须知:如何正确求助?哪些是违规求助? 9559576
关于积分的说明 21750809
捐赠科研通 7757392
什么是DOI,文献DOI怎么找? 3429167
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923